Arexis AB

Suède

Retour au propriétaire

1-12 de 12 pour Arexis AB Trier par
Recheche Texte
Affiner par
Type PI
        Marque 7
        Brevet 5
Juridiction
        États-Unis 8
        Europe 2
        International 2
Date
2025 1
2024 1
2023 1
Avant 2021 9
Classe IPC
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps 3
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus 3
A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza 2
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN 2
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification 2
Voir plus
Classe NICE
05 - Produits pharmaceutiques, vétérinaires et hygièniques 5
42 - Services scientifiques, technologiques et industriels, recherche et conception 3
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture. 3
36 - Services financiers, assurances et affaires immobilières 2
41 - Éducation, divertissements, activités sportives et culturelles 2
Voir plus

1.

Miscellaneous Design

      
Numéro d'application 1879299
Statut Enregistrée
Date de dépôt 2025-04-21
Date d'enregistrement 2025-04-21
Propriétaire Arexis AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders. Medical services; medical information services; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of genetic diseases and disorders, via an online database that collects data and information on genetic diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, via an online database that collects data and information on cardiovascular, metabolic, neurological and inflammatory diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

2.

TRYNGOLZA

      
Numéro d'application 1822011A
Statut Enregistrée
Date de dépôt 2024-04-15
Date d'enregistrement 2024-04-15
Propriétaire Arexis AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders. Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders, online journals, namely, blogs featuring information on genetic diseases and disorders; education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, online journals, namely, blogs featuring information on diseases and disorders of the cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Pharmaceutical research and development in the field of genetic diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of genetic diseases and disorders, research in the field of genetic diseases and disorders; pharmaceutical research and development in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, research in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Medical services; medical information services; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing medical and healthcare information via an online database in the field of genetic diseases and disorders; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing medical and healthcare information via an online database in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

3.

TRYNGOLZA

      
Numéro d'application 018960019
Statut Enregistrée
Date de dépôt 2023-12-05
Date d'enregistrement 2024-04-16
Propriétaire Arexis AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders; pharmaceuticals; pharmaceutical preparations. Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders, online journals, namely, blogs featuring information on genetic diseases and disorders; education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, online journals, namely, blogs featuring information on diseases and disorders of the cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Pharmaceutical research and development in the field of genetic diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of genetic diseases and disorders, compiling data for research purposes in the field of genetic diseases and disorders; pharmaceutical research and development in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, compiling data for research purposes in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Medical services; medical information services; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of genetic diseases and disorders, and collecting data and information on genetic diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, and collecting data and information on cardiovascular, metabolic, neurological and inflammatory diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

4.

SYNAGIS CONNECT

      
Numéro de série 88481687
Statut Enregistrée
Date de dépôt 2019-06-20
Date d'enregistrement 2021-01-05
Propriétaire AREXIS AB (Suède)
Classes de Nice  ? 36 - Services financiers, assurances et affaires immobilières

Produits et services

Patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs

5.

SYNAGIS CONNECT

      
Numéro de série 88481636
Statut Enregistrée
Date de dépôt 2019-06-20
Date d'enregistrement 2021-01-05
Propriétaire AREXIS AB (Suède)
Classes de Nice  ? 36 - Services financiers, assurances et affaires immobilières

Produits et services

Patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs

6.

Manufacturing method

      
Numéro d'application 15522472
Numéro de brevet 10625180
Statut Délivré - en vigueur
Date de dépôt 2015-10-30
Date de la première publication 2017-11-23
Date d'octroi 2020-04-21
Propriétaire Arexis AB (Suède)
Inventeur(s)
  • Choudhary, Sureshkumar
  • Mezghebe, Tesfu
  • Houchin, Mary
  • Vernooij, Eric
  • Peters, Marjo
  • Corcoran, Marta
  • Kim, Yoen Joo
  • Cao, Mingyan

Abrégé

This application is directed to a method of producing vials containing a composition comprising a recombinant protein. In some embodiments, the method comprises: (a) providing a container containing a composition comprising a recombinant protein optionally where the container has been stored under positive pressure; (b) applying a vacuum to the container containing a composition comprising a recombinant protein; (c) allowing the vacuum to degas the composition; and (d) filling vials with the de gassed composition comprising a recombinant protein.

Classes IPC  ?

  • B01D 19/00 - Dégazage de liquides
  • C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
  • C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

7.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Numéro d'application 14479612
Numéro de brevet 09499590
Statut Délivré - en vigueur
Date de dépôt 2014-09-08
Date de la première publication 2015-05-07
Date d'octroi 2016-11-22
Propriétaire AREXIS AB (Suède)
Inventeur(s)
  • Mcauliffe, Josephine
  • Palmer-Hill, Frances
  • Zhu, Qing
  • Suzich, Joann

Abrégé

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Classes IPC  ?

  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
  • G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

8.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Numéro d'application 13147051
Numéro de brevet 08852608
Statut Délivré - en vigueur
Date de dépôt 2009-12-23
Date de la première publication 2012-06-21
Date d'octroi 2014-10-07
Propriétaire AREXIS AB (Suède)
Inventeur(s)
  • Mcauliffe, Josephine
  • Palmer-Hill, Frances
  • Zhu, Qing
  • Suzich, Joann

Abrégé

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Classes IPC  ?

  • A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
  • A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
  • C12N 7/08 - Inactivation ou atténuationProduction de parties élémentaires de virus par passages successifs de virus
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

9.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Numéro d'application 12718476
Numéro de brevet 09096658
Statut Délivré - en vigueur
Date de dépôt 2010-03-05
Date de la première publication 2010-11-04
Date d'octroi 2015-08-04
Propriétaire AREXIS AB (Suède)
Inventeur(s)
  • Tous, Guillermo
  • Schenerman, Mark
  • Casas-Finet, Jose
  • Wei, Ziping
  • Pfarr, David

Abrégé

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Classes IPC  ?

  • G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
  • G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
  • C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

10.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Numéro d'application 11230593
Numéro de brevet 07700720
Statut Délivré - en vigueur
Date de dépôt 2005-09-21
Date de la première publication 2006-05-11
Date d'octroi 2010-04-20
Propriétaire AREXIS AB (Suède)
Inventeur(s)
  • Tous, Guillermo
  • Schenerman, Mark
  • Casas-Finet, Jose
  • Wei, Ziping
  • Pfarr, David

Abrégé

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Classes IPC  ?

11.

AREXIS

      
Numéro d'application 004294328
Statut Enregistrée
Date de dépôt 2005-02-17
Date d'enregistrement 2006-10-06
Propriétaire Arexis AB (Suède)
Classes de Nice  ?
  • 03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Cosmetics; cosmetic preparations for skin care. Pharmaceutical preparations, not including pharmaceutical preparations for the treatment of diseases of the central nervous system; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies. Scientific and technological services and research and design relating thereto; licensing of intellectual property.

12.

SYNAGIS

      
Numéro de série 75408414
Statut Enregistrée
Date de dépôt 1997-12-19
Date d'enregistrement 1999-05-25
Propriétaire AREXIS AB (Suède)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

[ humanized monoclonal antibody against respiratory syncytial virus for scientific research use ] humanized monoclonal antibody against respiratory syncytial virus for medical clinical use